Search
Charles River Laboratories International Inc
CRLAdd to Watchlist
342.690USD
-3.110-0.90%
Close 11-11 16:00（ET）
16.36BMarket Cap
LossP/E TTM
After-hours 19:00 (ET)342.690USD-0.105-0.03%
After-hours 19:00 (ET)Charles River Laboratories International Inc (CRL) Stock Price Target & Forecast
Analyst Rating
Based on 18 analysts giving stock ratings to Charles River Laboratories International Inc in the past month.
Buy
6 Strong Buy
8 Buy
4 Hold
0 Sell
0 Strong Sell
Target Price
313.738USD-12.71%
CRL Analyst Recommendation Trends
In the current month, CRL has received 8 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CRL average Analyst price target in the last month is 313.738.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
6
6
4
5
6
6
6
6
8
9
7
8
7
6
5
5
4
4
7
6
7
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
19
18
19
20
20
19
19
CRL Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CRL EPS is projected to reach 3.324 in FY2026Q4, following reported EPS of 6.967 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
1.94
2.74
2.97
3.32
2.86
Actual
-0.30
-0.03
6.97
--
--
Surprise
-115.61%
-101.13%
+134.35%
--
--
FAQs
What is Charles River Laboratories International Inc's expected revenue for the next quarter?
Charles River Laboratories International Inc's expected revenue is 963.13M.
How have Charles River Laboratories International IncCRL's recent earnings per share performed?
The market expectation was USD 6.97, while Charles River Laboratories International IncCRL's earnings per share (EPS) for the previous quarter was USD -0.03. EPS for the next quarter is expected at USD 3.32.
What is the analyst rating for Charles River Laboratories International Inc?
Based on the ratings of Charles River Laboratories International Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.